Participated · Series D · May 2026

CellCentric is a privately held, clinical-stage biotech company developing inobrodib, an orally bioavailable p300/CBP inhibitor. The lead program is in registration-enabling clinical trials for patients with relapsed/refractory multiple myeloma, and the company is enrolling a Phase 2 DOMMINO-1 study in the UK and US. CellCentric plans to initiate the global Phase 3 DOMMINO-2 trial in the second half of 2026. The company holds an IP portfolio and has clinical collaborations and strategic partnerships that provide external validation. Led by CEO Will West, CellCentric is based in Cambridge, UK, and maintains an additional office in Boston, MA. The article did not disclose revenue or other operating metrics.

Participated · Series A · Dec 2025

Syneron Bio develops macrocyclic peptide therapeutics using its proprietary, high-throughput Synova™ discovery platform. The company's pipeline is diversified across oncology, autoimmune, metabolic, and rare disease indications. Syneron Bio plans to use the Series B proceeds to further evolve and scale its intelligence-driven Synova™ platform and to accelerate progression of multiple core programs into clinical development. The financing, which strengthened the company's cash position, includes participation from global life-science funds, sovereign wealth, strategic corporates and existing shareholders. Syneron Bio highlights improving platform efficiency and success rates as central to its future discovery and development efforts. The company is headquartered in Beijing.

Participated · Seed · Oct 2024

Promise Bio builds a cloud-based AI platform that detects different post-translational modifications (PTMs) in proteins from a single blood sample, replacing the need for separate tests for each PTM. The company emphasizes that it is focused on precision medicine for autoimmune diseases rather than being another AI drug-discovery firm. Founded in January 2023 and based in Tel Aviv, Promise Bio operated in stealth until recently. It is already working with multiple large hospitals in the U.S. and Israel and with drug companies including AstraZeneca and Pfizer. The company closed an $8.3M seed round in April 2023, led by Awz Ventures with strategic participation from AstraZeneca and Pfizer. Promise Bio plans to use the funds to hire additional staff and to build a database of PTM datapoints to support future research and development.

Participated · Equity · Jul 2024

CytoReason develops computational disease models and AI tools that provide molecular-level insights to inform therapeutic R&D decisions. Its platform is used to prioritize targets and indications, stratify patient populations, compare drugs, and optimize R&D portfolios. The company says its models improve probability of phase 2 success and shorten R&D timelines. Six of the world’s top ten pharma companies use CytoReason’s technology across immunology, inflammation, immuno-oncology, metabolism and other areas. Since expanding its Pfizer partnership in 2022, CytoReason has added three major pharma partnerships and broadened coverage to CNS-related diseases. Its teams publish regularly in top journals (Nature, Cell, Gut) and produced 20 peer-reviewed articles in 2023. The company will use new funding to expand model applications into additional indications, grow proprietary molecular and clinical data, and establish a Cambridge, Massachusetts office.

Participated · Series A · Jan 2024

COUR Pharma develops first-in-class antigen-specific immune tolerance therapies using a proprietary nanoparticle platform that encapsulates disease-relevant antigens to reprogram autoimmune responses. Its lead program, CNP-103, encapsulates four recombinant proteins and is designed to induce tolerance to antigens driving type 1 diabetes; it is currently in a Phase 2 randomized, double-blind, placebo-controlled trial (NCT06783309) in recently diagnosed adolescents and adults. COUR says the proteins in CNP-103 are believed to cover over 95% of known T1D-driving antigens and aims to prevent further islet cell destruction and preserve insulin production. The company is pursuing partnerships to advance CNP-104 for primary biliary cholangitis and CNP-106 for myasthenia gravis. COUR recently raised $50 million in a Series B to support the clinical advancement of CNP-103, with participation from strategic and venture investors including Lumira Ventures, Roche Venture Fund, and Sanofi.